公开(公告)号：US20190290630A1

公开(公告)日：2019-09-26

申请号：US16229150

申请日：2018-12-21

Applicant: AMGEN INC.

Inventor： Sean Caenepeel ,  Jude Canon ,  Paul Hughes ,  Jonathan D. Oliner ,  Richard J. Rickles ,  Anne Y. Saiki

IPC: A61K31/451 ,  A61K31/365 ,  A61K31/635 ,  A61K31/704 ,  A61K31/706 ,  A61K31/166 ,  A61K31/7068 ,  A61K31/437 ,  A61K31/44 ,  A61K31/496 ,  A61K31/5025 ,  A61K31/519 ,  A61K31/506 ,  A61K31/4045

Abstract: The present invention provides combination therapy that includes an MDM2 inhibitor and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.

公开(公告)号：US20220280495A1

公开(公告)日：2022-09-08

申请号：US17470136

申请日：2021-09-09

Applicant: AMGEN INC.

Inventor： Sean Caenepeel ,  Jude Canon ,  Paul Hughes ,  Jonathan D. Oliner ,  Richard J. Rickles ,  Anne Y. Saiki

IPC: A61K31/45 ,  A61K31/7068 ,  A61P35/02 ,  A61K9/00 ,  A61K31/704

Abstract: The present invention provides combination therapy that includes an MDM2 inhibitor and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.

公开(公告)号：US10328062B2

公开(公告)日：2019-06-25

申请号：US15300690

申请日：2015-04-03

Applicant: AMGEN, INC.

Inventor： Sean Caenepeel ,  Angela Coxon ,  Zhiqiang Du ,  Paul Hughes ,  Robert Loberg ,  Gataree Ngarmchamnanrith ,  Beate Sable

IPC: A61K31/4375 ,  C12Q1/6886

Abstract: The present invention relates to methods of therapeutic treatment of cancer using selective tyrosine kinase inhibitors and cancer biomarkers, such as MET amplification and high Met expression for patient selection.

公开(公告)号：US10881648B2

公开(公告)日：2021-01-05

申请号：US16229150

申请日：2018-12-21

Applicant: AMGEN INC.

Inventor： Sean Caenepeel ,  Jude Canon ,  Paul Hughes ,  Jonathan D. Oliner ,  Richard J. Rickles ,  Anne Y. Saiki

IPC: A61K31/451 ,  A61K31/166 ,  A61K31/365 ,  A61K31/4045 ,  A61K31/437 ,  A61K31/44 ,  A61K31/496 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/519 ,  A61K31/635 ,  A61K31/704 ,  A61K31/706 ,  A61K31/7068 ,  A61P35/02 ,  A61P35/00

Abstract: The present invention provides combination therapy that includes an MDM2 inhibitor and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.